Modified Bromelain-Rx - Anatara Lifesciences

Drug Profile

Modified Bromelain-Rx - Anatara Lifesciences

Alternative Names: Detach™

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Anatara Lifesciences
  • Class Anti-inflammatories; Antidiarrhoeals; Cysteine endopeptidases; Skin disorder therapies
  • Mechanism of Action Bacterial growth inhibitors; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Diarrhoea

Most Recent Events

  • 07 Oct 2016 Modified Bromelain-Rx is available for licensing as of 07 Oct 2016. http://anataralifesciences.com/
  • 07 Oct 2016 Phase-I clinical trials in Diarrhoea in Australia (unspecified route) prior to October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top